AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 162 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,247 | +9.9% | 1,626,110 | +25.7% | 0.01% | +20.0% |
| Q2 2023 | $36,629 | +26.2% | 1,293,392 | +2.3% | 0.01% | +25.0% |
| Q1 2023 | $29,028 | -30.2% | 1,263,697 | -14.6% | 0.00% | -42.9% |
| Q4 2022 | $41,564 | -99.9% | 1,480,194 | +0.3% | 0.01% | 0.0% |
| Q3 2022 | $41,756,000 | -26.1% | 1,476,473 | -42.0% | 0.01% | 0.0% |
| Q2 2022 | $56,467,000 | -28.2% | 2,546,986 | -5.7% | 0.01% | -12.5% |
| Q1 2022 | $78,644,000 | -16.9% | 2,701,625 | -6.2% | 0.01% | -11.1% |
| Q4 2021 | $94,623,000 | -32.3% | 2,878,714 | -5.0% | 0.01% | -30.8% |
| Q3 2021 | $139,869,000 | -14.9% | 3,030,741 | +1.6% | 0.01% | -13.3% |
| Q2 2021 | $164,405,000 | +7.5% | 2,983,223 | +0.8% | 0.02% | 0.0% |
| Q1 2021 | $152,876,000 | +18.7% | 2,960,412 | -0.4% | 0.02% | +15.4% |
| Q4 2020 | $128,791,000 | +18.3% | 2,972,322 | -4.4% | 0.01% | 0.0% |
| Q3 2020 | $108,836,000 | -37.9% | 3,109,609 | -5.1% | 0.01% | -40.9% |
| Q2 2020 | $175,271,000 | +83.3% | 3,277,313 | +21.6% | 0.02% | +46.7% |
| Q1 2020 | $95,645,000 | -29.0% | 2,695,730 | -4.5% | 0.02% | -11.8% |
| Q4 2019 | $134,733,000 | +58.7% | 2,821,635 | +7.7% | 0.02% | +41.7% |
| Q3 2019 | $84,894,000 | -37.8% | 2,620,172 | -4.3% | 0.01% | -36.8% |
| Q2 2019 | $136,551,000 | -27.7% | 2,737,600 | -2.3% | 0.02% | -32.1% |
| Q1 2019 | $188,954,000 | +74.2% | 2,801,812 | +19.1% | 0.03% | +55.6% |
| Q4 2018 | $108,484,000 | -50.3% | 2,352,730 | -16.9% | 0.02% | -43.8% |
| Q3 2018 | $218,251,000 | -12.1% | 2,830,017 | -4.0% | 0.03% | -15.8% |
| Q2 2018 | $248,210,000 | -2.9% | 2,946,809 | -5.7% | 0.04% | -7.3% |
| Q1 2018 | $255,646,000 | +145.0% | 3,126,023 | +71.3% | 0.04% | +141.2% |
| Q4 2017 | $104,326,000 | -10.5% | 1,824,846 | +4.4% | 0.02% | -15.0% |
| Q3 2017 | $116,621,000 | +51.0% | 1,747,136 | +16.4% | 0.02% | +42.9% |
| Q2 2017 | $77,254,000 | -5.7% | 1,501,531 | +7.1% | 0.01% | -6.7% |
| Q1 2017 | $81,887,000 | +51.8% | 1,402,174 | +8.5% | 0.02% | +36.4% |
| Q4 2016 | $53,946,000 | -17.6% | 1,292,736 | +4.3% | 0.01% | -15.4% |
| Q3 2016 | $65,493,000 | +87.9% | 1,239,924 | +49.0% | 0.01% | +85.7% |
| Q2 2016 | $34,855,000 | +271.4% | 831,949 | +259.9% | 0.01% | +250.0% |
| Q1 2016 | $9,386,000 | -34.5% | 231,179 | +4.8% | 0.00% | -33.3% |
| Q4 2015 | $14,323,000 | -19.9% | 220,619 | -13.0% | 0.00% | -25.0% |
| Q3 2015 | $17,892,000 | -62.1% | 253,457 | -40.3% | 0.00% | -60.0% |
| Q2 2015 | $47,218,000 | -24.2% | 424,854 | -35.7% | 0.01% | -23.1% |
| Q1 2015 | $62,260,000 | +416.6% | 660,232 | +513.7% | 0.01% | +333.3% |
| Q4 2014 | $12,053,000 | -74.2% | 107,580 | -89.5% | 0.00% | -70.0% |
| Q2 2014 | $46,732,000 | +666.7% | 1,019,913 | +367.8% | 0.01% | +400.0% |
| Q3 2013 | $6,095,000 | – | 218,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |